Skip to main content
Premium Trial:

Request an Annual Quote

ParAllele Licenses SNPs from Genaissance for MegAllele; Genaissance to Market Product for Research Use

NEW YORK, April 6 (GenomeWeb News) - Genaissance Pharmaceuticals and ParAllele BioScience today announced a joint licensing and co-marketing agreement for ParAllele's upcoming MegAllele DME-T assay panel.


Under the terms of the agreement, ParAllele will license more than 400 proprietary SNPs from Genaissance. These will be combined with SNPs from the public domain to make up a total of around 1,500 SNPs that ParAllele will incorporate into MegAllele DME-T, which will assay around 160 genes that are involved in drug metabolism and transport pathways.


Genaissance will market the panel for research use only in GLP-compliant environments.


In mid-March, ParAllele said that it had teamed with Eli Lilly to make the DME-T panel available for contract research organizations to genotype Lilly's clinical trial participants. This application for the assay panel is expected to be available by August or September.


ParAllele also said at the time that it would file for FDA approval to market a version of the assay as an in vitro diagnostic.


The panel will run on Affymetrix's GeneChip platform.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.